News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
The firm launched a study this year to validate the new CRC-specific immune-transcriptomic assay, aiming to obtain regulatory approval in Europe.
The company also reported a decline in its net loss for the quarter on lower operating expenses due to a recent reorganization that included layoffs.
The firm said that its HSV and varicella-zoster virus assay delivers answers for related herpes conditions in about an hour.
The firm is developing a multipanel test and an antibiotic resistance panel to augment its recently CE marked chlamydia and gonorrhea assay.
The firm will use the proceeds to scale operations, advance its companion diagnostics program, and further expand its minimal residual disease program.
